China Medical System Unit Wins Singapore Approval for Vitiligo Cream
China Medical System said its unit Rxilient Medical received Singapore approval for a vitiligo cream.
Story updates
08:51:49 AM UTC
SquawkNews
SHENZHEN, CHINA, Nov. 04, 2026 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Rxilient Medical received approval from the Health Sciences Authority of Singapore (HSA) on 3 November 2026 for the New Drug Application (NDA…
08:52:06 AM UTC
SquawkNews
Singapore’s HSA approved CMS subsidiary Rxilient Medical’s ruxolitinib phosphate cream for non-segmental vitiligo with facial involvement in adults and adolescents aged 12 and older.Material DetailsContext by AI AnalystThis is a further regional regulatory milestone for a product CMS says is alread…